This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Ablation Atrial Fibrillation Outcomes 
DAIC
APRIL 18, 2024
Based on continuous monitoring of early recurrence of atrial tachyarrhythmia immediately after patients have undergone atrial fibrillation ablation, Musat et al. ERAT is often attributed to transient inflammation induced by tissue damage during ablation and short-term imbalances in autonomic innervation.
Cardiovascular Diabetology
APRIL 4, 2024
This study investigates the relationship between triglyceride-glucose (TyG) index trajectories and the results of ablation in patients with stage 3D atrial fibrillation (AF).
DAIC
MAY 18, 2024
During its Annual Conference, HRS 2024, the Heart Rhythm Society (HRS) announced findings from three new studies demonstrating the safety and efficacy of pulsed field ablation (PFA), a nonthermal ablation treatment for patients with atrial fibrillation (AF).
DAIC
DECEMBER 29, 2023
Outcomes of ablation with the FARAPULSE PFA System – a nonthermal treatment in which electric fields selectively ablate heart tissue – will be compared to outcomes following use of anti-arrhythmic drug (AAD) therapy, which is commonly prescribed for patients living with persistent AF. The company now anticipates U.S.
HeartRhythm
APRIL 8, 2024
There is insufficient data assessing the regional differences in catheter ablation outcomes for atrial fibrillation (AF) in the United States.
Medical Xpress - Cardiology
MAY 18, 2024
Atrial fibrillation (AF) is the most common form of arrythmia or irregular heartbeat worldwide, impacting millions of people in the U.S.
DAIC
MARCH 28, 2024
The VARIPULSE Platform is comprised of the VARIPULSE Catheter, a fully integrated variable-loop multielectrode catheter; the TRUPULSE Generator, a pulsed field ablation (PFA) generator; and the CARTO 3 System VARIPULSE Software, which provides full integration with the world's leading 3D cardiac mapping system.
HeartRhythm
SEPTEMBER 20, 2024
Data on long-term effects of catheter ablation versus antiarrhythmic drugs (AAD) on health-related quality of life (HRQoL) and atrial fibrillation (AF) burden are limited.
HeartRhythm
MAY 15, 2024
With the exponential growth of catheter ablation (CA) for atrial fibrillation (AF), there is increasing interest in associated healthcare costs.
Frontiers in Cardiovascular Medicine
JANUARY 16, 2024
Introduction Catheter ablation is an effective and safe strategy for treating atrial fibrillation patients. Nevertheless, studies on the long-term outcomes of catheter ablation in patients with dilated cardiomyopathy are limited. years following catheter ablation.
Frontiers in Cardiovascular Medicine
FEBRUARY 7, 2024
Background Efforts to maintain sinus rhythm in patients with persistent atrial fibrillation (PsAF) remain challenging, with suboptimal long-term outcomes. Methods All patients undergoing convergent PsAF ablation at our centre were retrospectively analysed. Twelve (50%) patients were obese.
DAIC
JULY 24, 2024
The collaboration, according to a written statement issued by the company, aims to address challenges in capturing and analyzing cardiac signals to help physicians enhance patient outcomes for atrial fibrillation procedures. Our mission to combat complex heart rhythm diseases relies on optimizing interoperability.
DAIC
FEBRUARY 2, 2024
Titled "Real-world Data Affirms Safety and Effectiveness of Low/Zero Fluoroscopy Atrial Fibrillation Ablation," the study was presented as a late-breaker at the 29th Annual International AF Symposium. This is the most commonly used ablation catheter in the world for RF ablation and is fully integrated with the CARTO 3 System.
105 
DAIC
FEBRUARY 6, 2024
EGF mapping allows physicians to detect EGF sources and is designed to individualize ablation strategies based on underlying pathophysiologic mechanisms to potentially improve outcomes. By guiding ablation therapy, [EGF mapping] can enable clinicians to provide personalized, highly targeted treatment."
104 
Journal of Cardiovascular Electrophysiology
JANUARY 28, 2024
Abstract Introduction Some previous studies have reported that a first-step ethanol infusion into the vein of Marshall (EIVOM) with touch-up radiofrequency (RF) ablation can facilitate mitral isthmus (MI) block and improves the ablation outcomes in persistent atrial fibrillation (PeAF) patients. 0.78, p = .006).
Med Page Today
DECEMBER 21, 2023
(MedPage Today) -- For patients undergoing catheter ablation for atrial fibrillation (Afib), there was no signal that a brief course of colchicine reduced atrial arrhythmia recurrence or improved clinical outcomes when taken for 10 days starting.
99 
Journal of the American Heart Association
DECEMBER 1, 2023
BackgroundThe incidence and type of complications following catheter ablation of atrial fibrillation have been extensively examined, but the impact associated with these complications on the length of stay and hospitalization costs is unknown.Methods and ResultsThis cohort study included 20 117 adult patients (mean age 62.6±11.4 years,
Frontiers in Cardiovascular Medicine
JANUARY 31, 2024
Background Pulmonary vein isolation with wide antral ablation leads to better clinical outcomes for the treatment of atrial fibrillation, but the isolation lesion is invisible in conventional cryoballoon ablation.
Frontiers in Cardiovascular Medicine
JANUARY 15, 2024
Background Catheter ablation (CA) for symptomatic atrial fibrillation (AF) offers the best outcomes for patients. Data were collected from the MPH AF Ablation Registry with the approval of the institutional research board. We present real-world 5-year follow-up data of AI-guided pulmonary vein isolation.
64 
Frontiers in Cardiovascular Medicine
JANUARY 28, 2024
Introduction A high recurrence rate of atrial fibrillation was monitored after catheter ablation for persistent atrial fibrillation. The primary outcome will be sinus rhythm maintenance rate over 12 months, monitored by random electrocardiogram and 24-h Holter electrocardiogram.
Open Heart
JANUARY 18, 2024
Introduction Three recent randomised controlled trials have demonstrated that pulmonary vein isolation as an initial rhythm control strategy with cryoablation reduces atrial arrhythmia recurrence in patients with symptomatic paroxysmal atrial fibrillation (PAF) compared with antiarrhythmic drug (AAD) therapy.
DAIC
MAY 15, 2024
a medical device company dedicated to advancing ablation treatment for cardiac arrythmias, announced its participation at the Heart Rhythm 2024 conference, taking place in person at the Boston Convention & Exhibition Center and virtually, May 16-19, 2024. milla1cf Wed, 05/15/2024 - 19:05 May 15, 2024 — CardioFocus, Inc. ,
111 
Frontiers in Cardiovascular Medicine
DECEMBER 14, 2023
Typical atrial flutter commonly occurs in patients with atrial fibrillation (AF). Limited information exists regarding the effects of concurrent atrial flutter on the long-term outcomes of rhythm control. The data were obtained from a multicenter registry of cryoballoon ablation for AF ( n = 2,689).
Open Heart
DECEMBER 18, 2024
Introduction Pulsed-field ablation (PFA) is a novel modality for pulmonary vein isolation in patients with atrial fibrillation (AF). first-time AF ablation. first-time AF ablation. In first-time ablation cases, acute isolation of all pulmonary veins was achieved in 99.5% The patients were 32.1% of patients.
Open Heart
SEPTEMBER 19, 2024
Background The value of empirical superior vena cava isolation (SVCI) following pulmonary vein isolation (PVI) to improve the efficacy of radiofrequency catheter ablation (RFCA) for paroxysmal atrial fibrillation (PAF) remains controversial. RFCA was guided by quantitative AI in both groups. vs 81.5%, p=0.02). 95% CI 0.19
ADN Center of Excellence
MAY 17, 2024
It is with great pride that we announce the resounding success of ADN CoE' s AFib Ablation Training program, the second installment in our esteemed Ablation Series, held at the prestigious 9 Eylül University Heart Rhythm Management Centre. COMING AHEAD: www.adncoe.com
59 
Open Heart
JANUARY 18, 2024
Background The Heart Failure Association Pretest assessment, echocardiography and natriuretic peptide, functional testing and final aetiology (HFA-PEFF) score has been developed for diagnosing heart failure with preserved ejection fraction (HFpEF), which is frequently associated with atrial fibrillation (AF).
HeartRhythm
APRIL 9, 2024
Rhythm control is a cornerstone of atrial fibrillation (AF) management. Shorter time between diagnosis of AF and receipt of catheter ablation is associated with greater rates of therapy success.
HeartRhythm
JUNE 30, 2024
The association between hospital and physician procedure volume outcome has not been well evaluated for atrial fibrillation (AF) ablation in contemporary practice.
HeartRhythm
APRIL 30, 2024
Pulsed-field ablation (PFA) using a pentaspline catheter could safely, effectively, and rapidly treat patients with persistent atrial fibrillation (AF), achieving not only PVI but also left atrial posterior wall (LAPW) and mitral isthmus (MI) ablation.
HeartRhythm
DECEMBER 11, 2024
Asthma is a known risk factor for atrial fibrillation (AF), the most common sustained arrhythmia. While radiofrequency catheter ablation is effective in treating AF, the impact of asthma and its severity on ablation outcomes has not been previously explored.
Frontiers in Cardiovascular Medicine
MAY 1, 2024
BackgroundCatheter ablation is frequently used to manage recurrent atrial fibrillation (AF) resistant to drug therapy, with pulmonary vein isolation (PVI) as a key tactic. The reconnection of pulmonary veins was discovered primarily in the anterior region of the right superior PV and the superior portion of the left superior PV.
HeartRhythm
APRIL 30, 2024
Little is known about characteristics and long-term outcomes of catheter ablation (CA) for atrial fibrillation (AF) in young patients
HeartRhythm
APRIL 30, 2024
Pulmonary vein isolation is a well-established treatment for atrial fibrillation (AF). There is increasing evidence to suggest differences in outcomes between male and female patients. Despite the increasing evidence in support of catheter ablation for AF, women remain underrepresented in major clinical trials.
HeartRhythm
APRIL 30, 2024
Colchicine is recommended following cardiac surgery to reduce the risk of atrial fibrillation (AF); however, the data on its effect on the outcomes of catheter ablation (CA) of AF have remained controversial.
HeartRhythm
APRIL 30, 2024
Previous studies have shown that increased catheter stability during atrial fibrillation (AF) ablation improves procedural outcomes. High frequency jet ventilation (HF JV) has been utilized to decrease respiratory motion and improve catheter stability. However, the effect of HF JV on AF recurrence is unknown.
HeartRhythm
DECEMBER 12, 2024
The autonomic nervous system, through the ganglionated plexus (GP), is known to contribute to the arrhythmogenesis of atrial fibrillation (AF).
Journal of Cardiovascular Electrophysiology
NOVEMBER 11, 2024
This study of 16 patients with persistent left superior vena cava (PLSVC) undergoing atrial fibrillation ablation shows a 66.7% identification rate of PLSVC-related triggers and an 85% success rate in acute isolation or targeted ablation. However, a 46.7% Results The cohort's mean age was 51.917.9 years, 31.2%
Frontiers in Cardiovascular Medicine
OCTOBER 13, 2024
BackgroundThe autonomic nervous system (ANS) plays a significant role in atrial fibrillation (AF). Catheter ablation (CA) is a well-established treatment method for AF and significantly affects the ANS, including baroreceptor (BR) function. ResultsThe two groups did not show differences in terms of clinical or demographic data.
HeartRhythm
APRIL 30, 2024
The relationship between electrical and structural indices in predicting acute atrial fibrillation (AF) ablation outcomes is complex and not well established. Defining this relationship may improve procedural ablation targeting and refine our understanding of AF mechanisms
HeartRhythm
APRIL 30, 2024
The question of optimal timing for catheter ablation of atrial fibrillation (AF) to achieve best outcomes remains a crucial clinical issue. As AF occurs less frequently in younger patients, data regarding Diagnosis-to-Ablation Time (DAT) is especially limited in patients under the age of 55 years with persistent AF.
HeartRhythm
APRIL 30, 2024
Long-term outcome of radiofrequency ablation (RFA) for longstanding persistent atrial fibrillation (LSPAF) is generally poor. Pulsed field ablation (PFA) was expected to improve the outcome.
HeartRhythm
AUGUST 25, 2024
Atrial fibrillation (AF) is an age-related disorder closely linked to autonomic nervous system dysfunction. Neurofilament light chain (NFL) protein is a biomarker for neurodegenerative diseases.
ADN Center of Excellence
MAY 17, 2024
It is with great pride that we announce the resounding success of ADN CoE' s AFib Ablation Training program, the second installment in our esteemed Ablation Series, held at the prestigious 9 Eylül University Heart Rhythm Management Centre. COMING AHEAD: www.adncoe.com
52
Expert insights. Personalized for you.
We have resent the email to
Are you sure you want to cancel your subscriptions?
Let's personalize your content